MX2019013755A - Terapias de combinación para el tratamiento del cáncer. - Google Patents
Terapias de combinación para el tratamiento del cáncer.Info
- Publication number
- MX2019013755A MX2019013755A MX2019013755A MX2019013755A MX2019013755A MX 2019013755 A MX2019013755 A MX 2019013755A MX 2019013755 A MX2019013755 A MX 2019013755A MX 2019013755 A MX2019013755 A MX 2019013755A MX 2019013755 A MX2019013755 A MX 2019013755A
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancer
- combination therapies
- agent
- cancer
- parp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508363P | 2017-05-18 | 2017-05-18 | |
| US201762508481P | 2017-05-19 | 2017-05-19 | |
| US201762578204P | 2017-10-27 | 2017-10-27 | |
| PCT/US2018/033437 WO2018213732A1 (en) | 2017-05-18 | 2018-05-18 | Combination therapies for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013755A true MX2019013755A (es) | 2020-07-20 |
Family
ID=62705671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013755A MX2019013755A (es) | 2017-05-18 | 2018-05-18 | Terapias de combinación para el tratamiento del cáncer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11622961B2 (enExample) |
| EP (1) | EP3624850A1 (enExample) |
| JP (1) | JP2020520921A (enExample) |
| KR (1) | KR20200005662A (enExample) |
| CN (1) | CN110913911A (enExample) |
| AU (2) | AU2018270112A1 (enExample) |
| BR (1) | BR112019024135A2 (enExample) |
| CA (1) | CA3063715A1 (enExample) |
| IL (1) | IL270720A (enExample) |
| MA (1) | MA49144A (enExample) |
| MX (1) | MX2019013755A (enExample) |
| WO (1) | WO2018213732A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EA201992177A1 (ru) | 2017-03-27 | 2020-02-25 | Тесаро, Инк. | Композиции на основе нирапариба |
| CN110753684A (zh) | 2017-04-24 | 2020-02-04 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| EP3624850A1 (en) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Combination therapies for treating cancer |
| AU2018341479B2 (en) | 2017-09-26 | 2022-02-17 | Tesaro, Inc. | Niraparib formulations |
| KR20200086664A (ko) | 2017-09-30 | 2020-07-17 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| MA50618A (fr) | 2017-10-06 | 2020-08-12 | Tesaro Inc | Polyrhérapies et leurs utilisations |
| EP3749352A1 (en) * | 2018-02-05 | 2020-12-16 | Tesaro Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| AU2019336345A1 (en) * | 2018-09-04 | 2021-04-15 | Pfizer Inc. | CD47 blockade with parp inhibition for disease treatment |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| US20220128544A1 (en) * | 2019-02-13 | 2022-04-28 | Creatv Microtech, Inc. | Ccr5-based methods for predicting overall and progression free survival in subjects having cancer |
| EP3966782A2 (en) | 2019-05-06 | 2022-03-16 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| WO2021163802A1 (en) * | 2020-02-20 | 2021-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors |
| CA3169303A1 (en) * | 2020-02-24 | 2021-09-02 | Xiaokun SHEN | Application of poly adp-ribose polymerase inhibitors in corona virus resistance |
| US20230123585A1 (en) * | 2020-03-03 | 2023-04-20 | The University Of Chicago | Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors |
| TWI877433B (zh) * | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| CN117042767A (zh) * | 2021-02-11 | 2023-11-10 | 丹娜法伯癌症研究院 | 使用sting激动剂治疗癌症的方法 |
| US20220275090A1 (en) * | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| WO2022218264A1 (en) * | 2021-04-11 | 2022-10-20 | Adagene Inc. | Combination therapies for treating cancer |
| US20240366584A1 (en) | 2021-06-21 | 2024-11-07 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| WO2023048506A1 (ko) * | 2021-09-23 | 2023-03-30 | 국립암센터 | 카르니틴 아실카르니틴 운반자 억제제 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| WO2023088436A1 (zh) * | 2021-11-18 | 2023-05-25 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法 |
| US20250073234A1 (en) * | 2022-01-04 | 2025-03-06 | Cornell University | Combination therapies including parp1 inhibitors |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| CN116370607A (zh) * | 2023-03-20 | 2023-07-04 | 中国人民解放军陆军军医大学第一附属医院 | 人重组hmgb1在制备治疗胶质瘤化疗增敏剂中的应用 |
| WO2024216089A1 (en) * | 2023-04-13 | 2024-10-17 | Bolt Biotherapeutics, Inc. | Anti-dectin-2 antibody combination therapy |
| CN118718000A (zh) * | 2023-06-19 | 2024-10-01 | 上海市第六人民医院 | 药物组合物及其在制备治疗肾癌的药物中的用途 |
| CN116726187B (zh) * | 2023-07-26 | 2025-09-30 | 珠海市人民医院 | 一种小分子配体-鲁卡帕尼偶联物及其制备方法 |
| KR20250156324A (ko) * | 2024-04-25 | 2025-11-03 | 한국 한의학 연구원 | 루카파립 캄실레이트를 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0325199B1 (en) | 1988-01-19 | 1993-10-27 | Takeda Chemical Industries, Ltd. | Fumagillin as angiostatic agent |
| KR0141692B1 (ko) | 1988-09-01 | 1998-06-01 | 우메모또 요시마사 | 맥관 형성 억제제 |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20090275619A1 (en) | 2006-04-03 | 2009-11-05 | BOUERES Julia | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors |
| EA016079B1 (ru) | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CA2705417A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| JP2011503111A (ja) | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| CN101959429B (zh) | 2008-01-08 | 2014-09-10 | 阿克塞利亚制药公司 | 抗微生物肽系统的激动剂 |
| NZ586675A (en) * | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR20110113648A (ko) | 2009-02-04 | 2011-10-17 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제와 함께 성장인자 억제제를 사용한 폐암의 치료 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| DK3012329T3 (da) | 2010-06-18 | 2017-11-20 | Myriad Genetics Inc | Fremgangsmåder og materialer til at vurdere tab af heterozygositet |
| DK2609216T3 (en) | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Methods to predict anti-cancer response |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013273466B2 (en) | 2012-06-07 | 2018-11-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| DK2928865T3 (en) | 2012-12-07 | 2018-06-18 | Merck Sharp & Dohme | BIOCATALYTIC TRANSAMINATION PROCEDURE |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
| AR095363A1 (es) | 2013-03-15 | 2015-10-14 | Genentech Inc | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US20180163271A1 (en) | 2014-01-16 | 2018-06-14 | Clovis Oncology, Inc. | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity |
| AU2015210886A1 (en) | 2014-01-29 | 2016-09-01 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| EP3148336B1 (en) * | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| EP3230472A4 (en) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| EP3277321B1 (en) | 2015-04-01 | 2024-08-14 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| HK1251474A1 (zh) | 2015-06-08 | 2019-02-01 | 豪夫迈‧罗氏有限公司 | 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法 |
| AU2016281622C1 (en) | 2015-06-25 | 2021-11-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| PL3337467T3 (pl) | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| WO2017075091A1 (en) | 2015-10-26 | 2017-05-04 | Medivation Technologies, Inc. | Treatment of small cell lung cancer with a parp inhibitor |
| JP6865762B2 (ja) | 2016-02-15 | 2021-04-28 | アストラゼネカ アクチボラグ | セジラニブの一定間欠投与を含む方法 |
| FI3478286T3 (fi) | 2016-06-29 | 2024-03-14 | Tesaro Inc | Menetelmiä munasarjasyövän hoitamiseksi |
| WO2018059437A1 (en) | 2016-09-27 | 2018-04-05 | Beigene, Ltd. | Treatment cancers using combination comprising parp inhibitors |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| EP3565844B8 (en) | 2017-01-09 | 2023-04-12 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| JP7118073B2 (ja) | 2017-01-09 | 2022-08-15 | テサロ， インコーポレイテッド | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
| BR112019020191A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro Inc | formulações de niraparib |
| EA201992177A1 (ru) | 2017-03-27 | 2020-02-25 | Тесаро, Инк. | Композиции на основе нирапариба |
| CN110753684A (zh) | 2017-04-24 | 2020-02-04 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| SG11201909395TA (en) | 2017-04-27 | 2019-11-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| EP3624850A1 (en) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Combination therapies for treating cancer |
| WO2019005762A1 (en) | 2017-06-26 | 2019-01-03 | Abbvie Inc. | TREATMENT OF NON-SMALL CELL LUNG CANCER |
| AU2018341479B2 (en) | 2017-09-26 | 2022-02-17 | Tesaro, Inc. | Niraparib formulations |
| KR20200086664A (ko) | 2017-09-30 | 2020-07-17 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| MA50618A (fr) | 2017-10-06 | 2020-08-12 | Tesaro Inc | Polyrhérapies et leurs utilisations |
| CA3087060A1 (en) | 2017-12-27 | 2019-07-04 | Tesaro, Inc. | Methods of treating cancer |
| EP3749352A1 (en) | 2018-02-05 | 2020-12-16 | Tesaro Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| EA201992594A1 (ru) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | Комбинированные терапии для лечения рака |
| US11970530B2 (en) | 2020-08-13 | 2024-04-30 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-05-18 EP EP18733393.5A patent/EP3624850A1/en not_active Withdrawn
- 2018-05-18 US US16/614,131 patent/US11622961B2/en active Active
- 2018-05-18 JP JP2019563582A patent/JP2020520921A/ja active Pending
- 2018-05-18 WO PCT/US2018/033437 patent/WO2018213732A1/en not_active Ceased
- 2018-05-18 AU AU2018270112A patent/AU2018270112A1/en not_active Abandoned
- 2018-05-18 CN CN201880047169.9A patent/CN110913911A/zh active Pending
- 2018-05-18 MX MX2019013755A patent/MX2019013755A/es unknown
- 2018-05-18 KR KR1020197037232A patent/KR20200005662A/ko not_active Ceased
- 2018-05-18 BR BR112019024135-3A patent/BR112019024135A2/pt not_active IP Right Cessation
- 2018-05-18 MA MA049144A patent/MA49144A/fr unknown
- 2018-05-18 CA CA3063715A patent/CA3063715A1/en active Pending
-
2019
- 2019-11-17 IL IL270720A patent/IL270720A/en unknown
-
2021
- 2021-08-09 AU AU2021215113A patent/AU2021215113A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11622961B2 (en) | 2023-04-11 |
| MA49144A (fr) | 2020-03-25 |
| IL270720A (en) | 2020-01-30 |
| US20210008053A1 (en) | 2021-01-14 |
| EP3624850A1 (en) | 2020-03-25 |
| BR112019024135A2 (pt) | 2020-06-02 |
| CN110913911A (zh) | 2020-03-24 |
| JP2020520921A (ja) | 2020-07-16 |
| CA3063715A1 (en) | 2018-11-22 |
| AU2021215113A1 (en) | 2021-08-26 |
| KR20200005662A (ko) | 2020-01-15 |
| AU2018270112A1 (en) | 2019-12-12 |
| WO2018213732A1 (en) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907395B (en) | Combination therapies for treating cancer | |
| ZA202501583B (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| MY193229A (en) | Pd-l1 antagonist combination treatments | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| PH12019502259A1 (en) | Glucocorticoid receptor modulators to treat cervical cancer | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| NZ756730A (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
| MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
| MX2015011428A (es) | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. | |
| MX2022001249A (es) | Tratamiento de tumores evasivos inmunitarios. | |
| BR112018075660A2 (pt) | métodos de tratamento de câncer de pâncreas | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| MX2016014007A (es) | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. | |
| MX2024006768A (es) | Compuestos y usos de los mismos. | |
| MX2020004960A (es) | Asociacion de activos para tratar el cancer de prostata. | |
| MX2021003062A (es) | Terapia combinada para tratar el cancer de sangre. | |
| EA201992594A1 (ru) | Комбинированные терапии для лечения рака | |
| MX2018015893A (es) | Compuestos anti-cancer. | |
| MX2022003190A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
| MX393477B (es) | Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas. |